Form 4: Acorn Bioventures Increases Stake in OnKure Therapeutics

Acorn Bioventures, L.P. reports acquiring additional shares of OnKure Therapeutics, Inc. at $1.85 per share, increasing its beneficial ownership.

Summary

• On May 15, 2025, Acorn Bioventures, L.P. acquired 270,270 shares of OnKure Therapeutics, Inc. common stock at a price of $1.85 per share.
• Following this transaction, Acorn Bioventures, L.P. directly owns 1,709,944 shares.
• On the same day, Acorn Bioventures 2, L.P. acquired 1,129,730 shares at $1.85 per share, holding them indirectly.
• Anders Hove, as manager of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, disclaims beneficial ownership except to the extent of his pecuniary interest.
• The report clarifies that it should not be deemed an admission of beneficial ownership for Section 16 purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a routine transaction. The increased stake could be seen as positive, but the disclaimers temper any strong positive interpretation.

Positives

• Acorn Bioventures' increased investment in OnKure Therapeutics could signal confidence in the company's future prospects.
• The acquisition of shares at $1.85 may indicate a perceived undervaluation or potential for growth.

Risks

• Anders Hove disclaims beneficial ownership, which could suggest a limited personal stake in the company's performance.
• The filing explicitly states that the report is not an admission of beneficial ownership, potentially indicating a complex ownership structure.

Management Comments

• Anders Hove, as manager of Acorn Capital Advisors GP, LLC and Acorn Capital Advisors GP 2, LLC, disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), except to the extent of its or his pecuniary interest therein, if any.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders and major shareholders, providing transparency to the market.

Stakeholder Impact

• The increased stake by Acorn Bioventures could positively influence shareholder confidence.
• The transaction may have a limited direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

OnKure Therapeutics, Acorn Bioventures, Beneficial Ownership, Form 4, Stock Acquisition, Anders Hove